Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kirsten Kaiser"'
Publikováno v:
Clinical Therapeutics. 35:950-966
Objectives This study investigated the efficacy and tolerability of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol)**Trademark: Flutiform® (Jagotec AG, Muttenz, Switzerland)., administered twice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d4587eaa3fe9d04c38fa58a48864af1
https://doi.org/10.1016/j.clinthera.2013.05.012
https://doi.org/10.1016/j.clinthera.2013.05.012
Publikováno v:
Respiratory Medicine. 107(2):180-195
Summary Background The inhaled corticosteroid, fluticasone propionate, and the long-acting β 2 -adrenergic agonist, formoterol fumarate, are both highly effective treatments for bronchial asthma. This study (NCT00393952/EudraCT number: 2006-005989-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc2fb00521d9137a630bb6d674185465
Autor:
Birgit Grothe, Kirsten Kaiser, Tammy McIver, Sanjeeva Dissanayake, Adel H. Mansur, Alberto Papi, Tetyana Pertseva
Publikováno v:
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Background: A primary goal of asthma management is the reduction of exacerbation risk. We assessed the occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations) with long-term fluticasone/formoterol therapy, and compared it with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9e37c6c9fa211f08dbfb1bccb15cf6
http://hdl.handle.net/11392/2352005
http://hdl.handle.net/11392/2352005
Publikováno v:
Respiratory Medicine. 106:S20-S28
SummaryInternational asthma management guidelines recommend a long-acting β2-agonist (LABA) as add-on therapy in patients whose asthma is not controlled by low-dose inhaled corticosteroid (ICS) monotherapy. Treatment with a single inhaler containing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771f7932745f27c5fa7f120e93a26503
Publikováno v:
Current medical research and opinion. 29(10)
To demonstrate the efficacy and safety of fluticasone propionate/formoterol fumarate (flutiform) in a pressurised metered-dose inhaler (pMDI) compared to two formulations of the fluticasone propionate component (Skyepharma fluticasone [SKP FP] or Flo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3989a72bb778a103aeac7ea57df9fb75
https://pubmed.ncbi.nlm.nih.gov/23865726
https://pubmed.ncbi.nlm.nih.gov/23865726
Autor:
Adel H. Mansur, Kirsten Kaiser
Publikováno v:
Journal of aerosol medicine and pulmonary drug delivery. 26(4)
The long-term safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform(®)) was assessed.In an open-label study, mild to moderate-severe asthmatics (≥12 years; N=472) were treated tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e970884c8b9aa06a48f1a31527eae31b
https://pubmed.ncbi.nlm.nih.gov/23098325
https://pubmed.ncbi.nlm.nih.gov/23098325
Publikováno v:
BMC Pulmonary Medicine, Vol 12, Iss 1, p 67 (2012)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background This study investigated the efficacy and safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform®), administered twice daily (b.i.d.) via a single aerosol inhaler, compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a550122e8b2a8ccc8237a8254199cd76
http://www.biomedcentral.com/1471-2466/12/67
http://www.biomedcentral.com/1471-2466/12/67